The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.